Inhibitory effects of glycosaminoglycans on basal and stimulated transforming growth factor-1 expression in mesangial cells: Biochemical and structural considerations

Glycobiology

Volumn 21, Issue 8, 2011, Pages 1029-1037

  Bacilieri, Magdalena ^a   Naggi, Annamaria ^b   Ceol, Monica ^c   Schleicher, Erwin D ^d   Tosetto, Enrica ^c   Comoli, Maura ^b   Torri, Giangiacomo ^b   Moro, Stefano ^a   Palumbo, Manlio ^a   Gambaro, Giovanni ^e  

^a UNIVERSITY OF PADOVA   (Italy)

^b Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

chondroitin sulfates; fibrosis; glycosaminoglycans; transforming growth factor 1

Indexed keywords

CHONDROITIN 4 SULFATE; CHONDROITIN 6 SULFATE; DERMATAN SULFATE; HEPARIN; PHORBOL 13 ACETATE 12 MYRISTATE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOHYDRATE ANALYSIS; CELL PROLIFERATION; GENE EXPRESSION; MESANGIUM CELL; MOLECULAR WEIGHT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SULFATION;

ANIMALS; CARBOHYDRATE CONFORMATION; CELLS, CULTURED; GLYCOSAMINOGLYCANS; MESANGIAL CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; TRANSFORMING GROWTH FACTOR BETA1;

EID: 79960246274     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwr038     Document Type: Article

References (47)

1. Akagi Y, Isaka Y, Arai M, Kaneko T, Takenaka M, Moriyama T, Kaneda Y, Ando A, Orita Y, Kamada T, et al. 1996. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 50:148-155. (Pubitemid 26323708)
2. Almond A, Sheehaman JK. 2000. Glycosaminoglycan conformation: Do aqueous molecular dynamics simulations agree with X-ray fiber diffraction? Glycobiology. 10:329-338. (Pubitemid 30145205)
3. Bertini S, Bisio A, Torri G, Bensi D, Terbojevich M. 2005. Molecular weight determination of heparin and dermatan sulfate by size exclusion chromato-graphy with a triple detector array. Biomacromolecules. 6:168-173. (Pubitemid 40277012)
4. Border WA. 1992. Natural inhibitor of transforming growth factor β protects against scarring in experimental kidney disease. Nature. 360:361-364. (Pubitemid 23000677)
5. Border WA, Noble NA. 1994. Transforming growth factor beta in tissue fibro-sis. N Engl J Med. 331:1286-1292. (Pubitemid 24333194)
6. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. 1990. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature. 346:371-373.
7. Border WA, Ruoslahti E. 1992. Transforming growth factor-β: The dark side of tissue repair. J Clin Invest. 90:1-7.
8. Böttinger EP, Factor VM, Tsang ML, Weatherbee JA, Kopp JB, Qian SW, Wa k e field LM, Roberts AB, Thorgeirsson SS, Sporn MB. 1996. The recombinant proregion of transforming growth factor β1 (latency-associated peptide) inhibits active transforming growth factor in transgenic mice. Proc Natl Acad Sci USA. 93:5877-5882.
9. Casu B, Naggi A, Torri G. 2010. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol. 29:442-452.
10. Casu B, Petitou M, Provasoli M, Sinaÿ P. 1988. Conformational flexibility: A new concept for explaining binding and biological properties of iduronic acid-containing glycosaminoglycans. Trends Biochem Sci. 13:221-225.
11. Cavari S, Fiorelli G, Vannucchi S. 1994. Binding and growth-inhibitory effect of heparin and oligo-heparin (2kDa) in Balb/c 3T3 cells: Lack of effect on PDGF-or serum-induced inositol lipid turnover. Br J Pharmacol. 113:254-260. (Pubitemid 24271746)
12. Ceol M, Gambaro G, Sauer U, Baggio B, Anglani F, Forino M, Facchin S, Bordin L, Weigert C, Nerlich A, et al. 2000. Glycosaminoglycan therapy prevents TGF-β1 over-expression and pathological changes in renal tissue of long-term diabetic rats. J Am Soc Nephrol. 11:2324-2336.
13. Clarkson MR, Gupta S, Murphy M, Martin F, Godson C, Brady HR. 1999. Connective tissue growth factor: A potential stimulus for glomerulosclero-sis and tubulointerstitial fibrosis in progressive renal disease. Curr Opin Nephrol Hypertens. 8:543-548. (Pubitemid 30010391)
14. Del Prete D, Gambaro G, Lupo A, Anglani F, Brezzi B, Magistroni R, Graziotto R, Furci L, Modena F, Bernich P, et al. 2003. Precocious activation of genes of the renin angiotensin system and the fibrogenic cascade in IgA glomerulonephritis. Kidney Int. 64:149-159. (Pubitemid 36714167)
15. Eickelberg O, Centrella M, Reiss M, Kashgarian M, Wells RG. 2002. Betaglycan inhibits TGF-β signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem. 277:823-829. (Pubitemid 34952123)
16. Gambaro G, Cavazzana AO, Luzi P, Piccoli A, Borsatti A, Crepaldi G, Marchi E, Venturini AP, Baggio B. 1992. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int. 42:285-291.
17. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S, Milanesi C, Pesarini A, Borsatti A, Marchi E, et al. 1994. Treatment with a glycosa-minoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int. 46:797-806. (Pubitemid 24272038)
18. Gigli M, Ghiselli G, Torri G, Naggi A, Rizzo V. 1993. A comparative study of low-density lipoprotein interaction with glycosaminoglycans. Biochim Biophys Acta. 1167:211-217. (Pubitemid 23104917)
19. Guerrini M, Naggi A, Guglieri S, Santarsiero R, Torri G. 2005. Complex gly-cosaminoglycans: Profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Analyt Biochem. 337:35-47. (Pubitemid 40092776)
20. Hamer GK, Perlin AS. 1976. 13C NMR spectra of chondroitin sulfates and dermatan sulfate. Evidence for structural heterogeneity. Carbohydr Res. 49:37-48.
21. Ikawa Y, Ng PS, Endo K, Kondo M, Chujo S, Ishida W, Shirasaki F, Fujimoto M, Takehara K. 2008. Neutralizing monoclonal antibody to human connective tissue growth factor ameliorates transforming growth factor-β-induced mouse fibrosis. J Cell Physiol. 216:680-687.
22. Isaka Y, Akagi Y, Ando Y, Tsujie M, Sudo T, Ohno N, Border WA, Noble NA, Kaneda Y, Hori M, et al. 1999. Gene therapy by transforming growth factor-β receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. 55:465-475. (Pubitemid 29082873)
23. Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imai E, Noble NA, Border WA. 1996. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med. 2:418-423. (Pubitemid 26191913)
24. Ishihara M, Fedarko NS, Conrad HE. 1986. Transport of heparan sulfate into the nuclei of hepatocytes. J Biol Chem. 26:13575-13580. (Pubitemid 17196377)
25. Jaseja M, Rej RN, Sauriol F, Perlin AS. 1989. Novel regio-and stereo-selective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence. Can J Chem. 67:1449-1456. (Pubitemid 19248003)
26. Kashihara N, Maeshina Y, Makino H. 1997. Therapeutic intervention in glo-merulonephritis by oligonucleotides. Exp Nephrol. 5:126-131.
27. Kim S-J, Denhez F, Kim KY, Holt JT, Sporn MA, Roberts AB. 1989. Activation of the second promoter of the transforming growth factor-β1 gene by transforming growth factor-β1 and phorbol ester occurs through the same target sequences. J Biol Chem. 264:19373-19378. (Pubitemid 19285848)
28. Kolm-Litty V, Sauer U, Nerlich A, Lehmann R, Schleicher ED. 1998. High glucose-induced transforming growth factor ß1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest. 101:160-169. (Pubitemid 28058915)
29. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. 1993. Transforming growth factor-β1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci USA. 90:770-777.
30. Lloyd AG, Embrey G, Fowler LJ. 1971. Studies on heparin degradation-I: Preparation of [35S] sulfamate derivatives for studies on heparin degrading enzymes of mammalian origin. Biochem Pharmacol. 20:637-648.
31. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B. 1995. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science. 268:1336-1338.
32. Mulloy B, Linhardt RJ. 2001. Order out of complexity-protein structures that interact with heparin. Curr Opin Struct Biol. 11:623-628. (Pubitemid 32972027)
33. Nagasawa K, Inoue Y. 1976. Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr Res. 46:87-95.
34. Naggi A, De Cristofano B, Bisio A, Torri G, Casu B. 2001. Generation of anti-factor Xa active, 3-O-sulfated glucosamine-rich sequences by controlled desulfation of oversulfated heparins. Carbohydr Res. 336:283-290. (Pubitemid 33139761)
35. Naggi G, Torri P, Angiuli B, Casu M, Mantovani R, Pescador R, Porta R. 1989. Sulfamino-galactosaminoglycans, a new class of semi-synthetic polysaccharides. Preparation, characterization, and lipase-releasing properties. In: Biomedical and Biotechnological Advances in Industrial Polysaccharides. New York: Gordon and Breach. pp. 101-108.
36. Naggi A, Torri G, Casu B, Pangrazzi J, Abbadini M, Zametta M, Donati MB, Lansen J, Maffrand JP. 1987. Supersulfated heparin fragments, a new type of low-molecular-weight heparin. Physico-chemical and pharmacological properties. Biochem Pharmacol. 36:1895-1900. (Pubitemid 17100208)
37. Pannu J, Asano Y, Nakerakanti S, Smith E, Jablonska S, Blaszczyk M, ten Dijke P, Trojanowska M. 2008. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum. 58:2528-2537.
38. Pescador R, Porta R, Mantovani M, Prino G, Casu B, Naggi A, Torri G, Walenga JM, Hoppensteadt DA, Fareed J. 1991. Pharmacologic profile of sulfamino-galactosaminoglycans. Sem Thromb Hemost. 17:74-79.
39. Pisano C, Aulicino C, Vesci L, Casu B, Naggi A, Torri G, et al. 2005. Undersulfated, low-molecular-weight glycol-split heparin as an antiangio-genic VEGF antagonist. Glycobiology. 15:1C-6C. (Pubitemid 40227915)
40. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, Devitt ML, Horan GS, Weinreb PH, Lukashev ME, et al. 2008. Inhibition of integrin α(v)β6, an activator of latent transforming growth factor-β, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med. 177:82-90.
41. Raman R, Venkataraman G, Ernst S, Sasisekharan V, Sasisekharan R. 2003. Structural specificity of heparin binding in the fibroblast growth factor family of proteins. Proc Natl Acad Sci USA. 100:2357-2362. (Pubitemid 36297503)
42. Santini F, Bisio A, Guerrini M, Casu B, Yates E. 1997. Modifications under basic conditions on the minor sequences of heparin containing 2,3 or 2,3,6 sulfated glucosamine residues. Carbohydr Res. 302:103-108. (Pubitemid 27343482)
43. Savage JM, Gilotti AC, Granzow CA, Molina F, Lowe-Krentz LJ. 2001. Antibodies against a putative heparin receptor slow cell proliferation and decrease MAPK activation in vascular smooth muscle cells. J Cell Physiol. 187:283-293. (Pubitemid 32378353)
44. Shaklee PN, Conrad HE. 1986. The disaccharides formed by deaminative cleavage of N-deacetylated glycosaminoglycans. Biochem J. 235:225-236. (Pubitemid 16041995)
45. Sharma K, Jin Y, Guo J, Ziyadeh FN. 1996. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 45:522-530.
46. Varga J, Pasche B. 2009. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol. 5:200-206.
47. Weigert C, Brodbeck K, Haring HU, Gambaro G, Schleicher ED. 2001. Low-molecular-weight heparin prevents high glucose-and phorbol ester-induced TGF-beta 1 gene activation. Kidney Int. 60:935-943. (Pubitemid 34205793)